# Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

> **NCT05834543** · PHASE1,PHASE2 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 34 (actual)

## Conditions studied

- Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin
- **DRUG:** Penpulimab injection, Paclitaxel, Cisplatin
- **DRUG:** TQB2618 injection, Penpulimab injection, TQB3617capsules

## Key facts

- **NCT ID:** NCT05834543
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-05-26
- **Primary completion:** 2024-10-23
- **Final completion:** 2025-03-03
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05834543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05834543, "Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05834543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*